CTT Pharma Q3 2026: Cash Down to $12,625, Loss Widens to $127,064, Going Concern Stands
CTTH sits 40% above its 52-week low of $0.035 on light trading volume (0.2× avg).
Summary
CTT Pharma's Q3 2026 10-Q shows $12,625 of cash, a $127,064 quarterly loss and a reaffirmed going concern warning, with operations funded by share issuance rather than revenue.
Key Events · Earnings and Guidance · CTTH
-
Going Concern Doubt Reaffirmed
Note 3 states that net losses, negative operating cash flow and working capital deficits raise substantial doubt about the ability to continue as a going concern within one year of issuance.
-
Cash Falls to $12,625
Cash dropped from $15,359 at December 31, 2025 to $12,625 at September 30, 2026, against $37,347 of current liabilities, including $17,905 of related-party payables and a $19,442 related-party note.
-
Quarterly Loss Widens to $127,064
Net loss grew from $15,379 in Q3 2025 to $127,064 in Q3 2026, an increase of $111,675, driven by consulting fees rising from $5,000 to $112,000.
-
Funded by Share Issuance, Not Revenue
1,794,444 shares were issued in Q3 2026: 1,150,000 for services valued at $112,000 and 644,444 for $30,000 of cash. The company reported no revenue-producing activities.
Analysis · CTTH · Life Sciences
Cash stood at $12,625 on September 30, 2026 against $37,347 of current liabilities, and the company's own note says these conditions raise substantial doubt about its ability to continue as a going concern within one year. The quarterly loss widened to $127,064 from $15,379 a year earlier, almost entirely because consulting fees jumped to $112,000 from $5,000, much of it paid in shares rather than cash. Equity is the funding source: 1,794,444 shares were issued in the quarter, 1,150,000 of them for services valued at $112,000 and 644,444 for just $30,000 of cash. Management still plans to spend roughly $500,000 on a manufacturing facility, money it does not have and says it must raise through an ELOC or other financing that may not materialize. On top of the cash problem, the auditor resignation in October and the new PCAOB auditor engagement on October 27 add execution risk to the reporting chain.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTTH was trading at $0.05 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.9M. The 52-week trading range was $0.04 to $0.10. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.